The purpose of this study is to evaluate the long-term safety of SPARC0913. A multicenter, open label, non-randomized, uncontrolled, single group assignment, safety study of subjects with primary open angle glaucoma or ocular hypertension is planned. Subjects will receive study medication for a period of 24-weeks.
This is a multicenter, open label, non-randomized, single-arm, extension safety study to evaluate the long-term safety of SPARC0913. Subjects who completed the prior evaluator-masked clinical non-inferiority Study participated in the current study.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
161
One drop of SPARC0913 in affected eye once daily for 24 weeks
SPARC study site
High Point, North Carolina, United States
Number of Subjects With AEs
Subjects with treatment emergent adverse events
Time frame: 24 weeks
Mean Change in IOP From Baseline to Visit 7 (End of Evaluations Visit)
From the start of study (baseline visit) through week 24 (Visit 7, end of evaluations visit), the change in IOP was measured
Time frame: 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.